We claim:

- A method for treating neuropathic pain comprising:
 identifying a subject in need of such treatment; and
 providing the subject with an effective amount of at least one compound
 that selectively activates the M(1) receptor subtype, whereby one or more
 symptoms of the neuropathic pain are reduced.
- 2. The method of claim 1, wherein the subject presents hyperalgesia.
- 3. The method of claim 1, wherein the subject presents allodynia.
- 4. The method of claim 1, wherein the neuropathic pain is associated with diabetes, viral infection, irritable bowel syndrome, amputation, cancer, or chemical injury.
- 5. The method of claim 1, wherein the at least one compound that selectively activates the M(1) receptor subtype does not alleviate acute pain.
- 6. The method of claim 1, wherein the compound is selected from the group consisting of the compounds of Formulas VII, VIII, and IX:

(VIII)

(IX)

7. A method of identifying a compound that alleviates hyperalgesia or allodynia in a subject, comprising:

providing the subject with at least one muscarinic receptor test compound; and

determining if the at least one test compound reduces hyperalgesia or allodynia in the subject.

- 8. The method of claim 7, wherein the at least one test compound is selective for the M(1) or M(4) but not M(2) or M(3) receptor.
- 9. The method of claim 7, wherein the at least one test compound is selective for the M(1) receptor.
 - 10. The method of claim 7, wherein the hyperalgesia is thermal hyperalgesia.
 - 11. The method of claim 7, wherein the allodynia is tactile allodynia.
- 12. A pharmaceutical composition comprising an effective amount of at least one compound that selectively activates the M(1) receptor subtype in an amount effective to reduce one or more symptoms of neuropathic pain.
- 13. The composition of claim 12, wherein the compound is selected from the group consisting of the compounds of Formulas VII, VIII, and IX:

$$F = \bigcup_{N \in \mathbb{N}} \mathbb{N}$$